0000950170-23-063927.txt : 20231114 0000950170-23-063927.hdr.sgml : 20231114 20231114192302 ACCESSION NUMBER: 0000950170-23-063927 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20231110 FILED AS OF DATE: 20231114 DATE AS OF CHANGE: 20231114 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Brennan Aoife CENTRAL INDEX KEY: 0001714563 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-37566 FILM NUMBER: 231408622 MAIL ADDRESS: STREET 1: 200 SIDNEY STREET, SUITE 320 STREET 2: C/O SYNLOGIC, INC. CITY: CAMBRIDGE STATE: MA ZIP: 02139 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: SYNLOGIC, INC. CENTRAL INDEX KEY: 0001527599 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 261824804 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 301 BINNEY STREET STREET 2: SUITE 402 CITY: CAMBRIDGE STATE: MA ZIP: 02142 BUSINESS PHONE: 617-401-9975 MAIL ADDRESS: STREET 1: 301 BINNEY STREET STREET 2: SUITE 402 CITY: CAMBRIDGE STATE: MA ZIP: 02142 FORMER COMPANY: FORMER CONFORMED NAME: Mirna Therapeutics, Inc. DATE OF NAME CHANGE: 20110809 4 1 ownership.xml 4 X0508 4 2023-11-10 0001527599 SYNLOGIC, INC. SYBX 0001714563 Brennan Aoife C/O SYNLOGIC, INC. 301 BINNEY STREET, SUITE 402 CAMBRIDGE MA 02142 true true President and CEO false Stock Option (right to buy) 202.95 2023-11-10 4 D false 5591 D 2027-05-15 Common Stock 5591 0 D Stock Option (right to buy) 149.25 2023-11-10 4 D false 3733 D 2028-03-14 Common Stock 3733 0 D Stock Option (right to buy) 143.25 2023-11-10 4 D false 3600 D 2028-06-05 Common Stock 3600 0 D Stock Option (right to buy) 118.65 2023-11-10 4 D false 9999 D 2028-10-31 Common Stock 9999 0 D Stock Option (right to buy) 128.85 2023-11-10 4 D false 12332 D 2029-03-05 Common Stock 12332 0 D Stock Option (right to buy) 25.50 2023-11-10 4 D false 12352 D 2030-03-10 Common Stock 12352 0 D Stock Option (right to buy) 52.50 2023-11-10 4 D false 18999 D 2031-03-10 Common Stock 18999 0 D Stock Option (right to buy) 29.25 2023-11-10 4 D false 28943 D 2032-02-04 Common Stock 28943 0 D Stock Option (right to buy) 9.30 2023-11-10 4 D false 42999 D 2033-03-16 Common Stock 42999 0 D Stock Option (right to buy) 9.30 2023-11-10 4 D false 8666 D 2033-03-16 Common Stock 8666 0 D Stock Option (right to buy) 1.85 2023-11-10 4 A false 5591 A 2027-05-15 Common Stock 5591 5591 D Stock Option (right to buy) 1.85 2023-11-10 4 A false 3733 A 2028-03-14 Common Stock 3733 3733 D Stock Option (right to buy) 1.85 2023-11-10 4 A false 3600 A 2028-06-05 Common Stock 3600 3600 D Stock Option (right to buy) 1.85 2023-11-10 4 A false 9999 A 2028-10-31 Common Stock 9999 9999 D Stock Option (right to buy) 1.85 2023-11-10 4 A false 12332 A 2029-03-05 Common Stock 12332 12332 D Stock Option (right to buy) 1.85 2023-11-10 4 A false 12352 A 2030-03-10 Common Stock 12352 12352 D Stock Option (right to buy) 1.85 2023-11-10 4 A false 18999 A 2031-03-10 Common Stock 18999 18999 D Stock Option (right to buy) 1.85 2023-11-10 4 A false 28943 A 2032-02-04 Common Stock 28943 28943 D Stock Option (right to buy) 1.85 2023-11-10 4 A false 42999 A 2033-03-16 Common Stock 42999 42999 D Stock Option (right to buy) 1.85 2023-11-10 4 A false 8666 A 2033-03-16 Common Stock 8666 8666 D In accordance with the terms of the Synlogic, Inc. 2015 Equity Incentive Award Plan and the Company's 2017 Stock Incentive Plan (together the "Plans"), the Board of Directors of Synlogic, Inc. approved a stock option repricing pursuant to which option awards granted under the Plans were amended to reduce the exercise price to $1.85 per share, the closing stock price of the Company's Common Stock on November 10, 2023. Except for the modified exercise price, all other terms and conditions of each of the option awards will continue as set forth in the Plan and the applicable award agreements. The shares subject to this option are fully vested as of the date hereof. The shares subject to this option vest in approximately equal monthly installments beginning on April 1, 2020 through April 1, 2024. The shares subject to this option vest in approximately equal monthly installments beginning on April 1, 2021 through April 1, 2025. The shares subject to this option vest in approximately equal monthly installments beginning on February 4, 2022 through February 4, 2026. The shares subject to this option vest in approximately equal monthly installments beginning on April 1, 2023 through April 1, 2027. These performance-based stock options, granted on March 16, 2023, vest when the achievement of certain clinical and regulatory development milestones are met. /s/ Aoife Brennan 2023-11-14